Stephens Initiates Overweight Coverage on Candel Therapeutics, Citing Transformative Pipeline and Limited Competition
Candel earned a $15 stock rating. Its key drug, CAN-2409, is seen as transformative because it improves current treatments.
/ 1679 items
#XY↓
Regeneron Beats Wall Street Estimates on Strong Dupixent and Libtayo Sales
Regeneron Pharmaceuticals exceeds Q3 2025 expectations with $3.75B revenue, driven by blockbuster eczema drug Dupixent and cancer treatment Libtayo, despite Eylea competition challenges.
UnitedHealth Raises Profit Forecast After Beating Q3 Earnings Expectations
UnitedHealth Group exceeds Q3 earnings estimates and increases 2025 profit outlook, signaling recovery after earlier financial struggles and management shakeup under returning CEO Stephen Hemsley.
Universal Health Services Crushes Q3 Expectations, Raises Full-Year Outlook
Universal Health Services (UHS) beats Q3 earnings by $0.85 per share with revenue of $4.5B. Company raises 2025 guidance and announces $1.5B stock buyback expansion.
FDA Grants Orphan Drug Status to Pancreatic Cancer Treatment Daraxonrasib
Revolution Medicines' daraxonrasib receives FDA Orphan Drug Designation for pancreatic cancer treatment, offering hope for patients with limited options in this deadly disease.
Organon CEO Steps Down After Sales Practice Investigation
Organon's (OGN) CEO Kevin Ali resigns following internal probe into Nexplanon birth-control implant sales practices. Company appoints interim chief and implements corrective measures.